Table III.
Generic reporting table.
| Experimental | Control | Effect size estimate (95% CI) * | |
|---|---|---|---|
| N | N | ||
| Live birth event, no. (%)† | |||
| Singleton, no. (%) | |||
| Twin, no. (%) | |||
| Higher multiples, no. (%) | |||
| Viable pregnancy confirmed by ultrasound, no. (%)† | |||
| Singleton pregnancy, no. (%) | |||
| Twin pregnancy, no. (%) | |||
| Higher multiple pregnancy, no. (%) | |||
| Pregnancy loss‡ | |||
| Ectopic pregnancy, no. | |||
| Miscarriage, no. | |||
| Stillbirth, no. | |||
| Termination of pregnancy, no. | |||
| Gestational age at delivery (weeks of gestation), median (IQR)§ | |||
| Birthweight | |||
| Singleton, g. (mean, SD) | |||
| Twin, g. (mean, SD)‖ | |||
| Higher multiples, g (mean, SD)‖ | |||
| Neonatal mortality, no.¶ | |||
| Major congenital anomaly, no.# |
Effect size estimates and 95% CI should only be reported for live birth event and viable pregnancy confirmed by ultrasound. The remaining data should be summarized narratively.
For live birth event and viable pregnancy confirmed by ultrasound the number of participants randomized should be used as the denominator.
When considering twin and higher multiple pregnancies, pregnancy loss should be explicitly accounted for within the table footnote.
For gestational age at delivery reporting the mean and SD within the table footnote would support future meta-analysis.
The birthweight for each newborn infant of the multiple birth set should be reported.
If a member of a multiple birth set dies in the neonatal period this should be explicitly stated within the table footnote.
Reported as an infant with at least one major congenital anomaly detected. If a major congenital anomaly is identified in a member of a multiple set this should be explicitly stated within the table footnote.
g, grams; N, number of randomized participants; No, number of events; IQR, interquartile range.